The drug causes death due to heart failure in a patient with hidradenitis suppurativa

New emergence of fatal congestive heart failure associated with adalimumab use in a patient with recurrent hidradenitis suppurativa: a case report.

Hidradenitis suppurativa is a condition that causes small, painful bumps to form under the skin. Photo: shutterstock.

Tumor necrosis factor (TNF)-alpha inhibitors are essential treatments in many inflammatory conditions such as hidradenitis suppurativa (HS). However, like all treatments, it is not without risks.

The literature confirms that in rare cases it has been associated with complications such as heart failure, as witnessed by Puerto Rican medicine, which was recently reported. condition to create awareness

Conducting more studies on adalimumab and this adverse effect, as well as recognizing the need for more studies to find new treatment modalities for HS.

A 67-year-old male with a history of HS in its acute form, who was reported in his clinical history to have major depressive disorder, went to hospital with dyspnea, exertional fatigue, and leg edema two weeks later. treatment. Development.

According to the case report, symptoms started after restarting adalimumab for hidradenitis suppurativa. However, during his stay in the hospital, he was diagnosed with decompensated congestive heart failure (CHF), which occurs when the heart muscle does not pump blood as it should, often pooling and pooling in the lungs, causing shortness of breath.

The medical team decided to suspend taking the drug due to suspected side effects of it as a possible cause of your condition. Unfortunately, the patient died of heart failure and sepsis.

The unusual but life-threatening occurrence of heart failure secondary to the use of adalimumab warrants close attention by Partial care doctors Primary and specialists, emphasize the case authors, attached to the Manatee Medical Center, Ponce University of Health Sciences and the Department of Dermatology at the Medical Sciences Campus.

there The occurrence of this adverse event It may reduce the number of deaths associated with adalimumab and congestive heart failure, the report confirms.

The Hidradenitis suppurativa treatment It is challenging, as documented in the literature, and generally requires a multidisciplinary approach. This condition also does not have extensive treatment options, as adalimumab was the only treatment adequately approved by the Food and Drug Administration. Effective for severe cases from HS.

Access the status here.